HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?

  • Authors:
    • Guido Cimoli
    • Monica Valenti
    • Cristina Ottoboni
    • Silvio Parodi
  • View Affiliations

  • Published online on: April 1, 2001     https://doi.org/10.3892/ijo.18.4.759
  • Pages: 759-765
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A cellular isogenic system, in which wt-p53 expression level is challenged through human papilloma virus 16-E6 gene transfection, was previously developed in our laboratory. As an average trend, cancer lines bearing an inactivated p53 have a general tendency toward an increased resistance to chemotherapeutic agents. However, using the above isogenic system, the transfected line (A2780-N9) was found to be more sensitive to taxol than the parental one (A2780-WT). In a NCI meta-analysis study the average trend is that altered p53 status is related to cellular resistance to topoisomerase II inhibitors, while it is irrelevant in determining sensitivity/resistance to mitotic spindle poisons. We report that our E6 transfected line, previously shown to be hypersensitive to taxol, is also clearly hypersensitive to a topoisomerase II inhibitor (mitoxantrone). Differences in cytotoxicity are more evident after a shorter/more intense exposure, than after a milder/longer exposure, being A2780-WT 27-fold more resistant than the transfected clone in the former case. These differences seem to be related to the different activities () of E6 protein, among which shortening of p53 half-life is only one aspect. After mitoxantrone treatment A2780-N9 cells display also an increased propensity to apoptosis. In addition, a literature survey of E6 effects in transfected cancer cell lines, seems to suggest that chemosensitization to different classes of antineoplastic agents is the rule rather than the exception in these E6-based isogenic systems.

Related Articles

Journal Cover

April 2001
Volume 18 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cimoli G, Valenti M, Ottoboni C and Parodi S: HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?. Int J Oncol 18: 759-765, 2001.
APA
Cimoli, G., Valenti, M., Ottoboni, C., & Parodi, S. (2001). HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?. International Journal of Oncology, 18, 759-765. https://doi.org/10.3892/ijo.18.4.759
MLA
Cimoli, G., Valenti, M., Ottoboni, C., Parodi, S."HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?". International Journal of Oncology 18.4 (2001): 759-765.
Chicago
Cimoli, G., Valenti, M., Ottoboni, C., Parodi, S."HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?". International Journal of Oncology 18, no. 4 (2001): 759-765. https://doi.org/10.3892/ijo.18.4.759